Donaldson Enters into Agreement to Acquire Minority Stake in Medica, S.p.A.
2024年4月29日 - 8:00PM
ビジネスワイヤ(英語)
Donaldson Company, Inc. (NYSE: DCI) (Donaldson or the Company),
a leading worldwide provider of innovative filtration products and
solutions, today announced it has entered into a definitive
agreement allowing the Company to purchase a 49% stake in Medica
S.p.A. (Medica). Medica is a leader in hollow fiber membrane
filtration technology for medical device applications and water
purification. Headquartered in Medolla, Italy, the Company has over
700 employees globally and generated €80 million of revenue in
calendar 2023.
Founded in 1985, Medica’s innovative hollow fiber membrane
filtration products are used for blood purification in numerous
applications including dialysis, continuous renal replacement
therapies (CRRT), and therapeutic apheresis. The Company’s products
and technologies are also used in the microbiological purification
of water, as well as automation solutions for disposable medical
device manufacturing.
“Hollow fiber membrane filtration is a fundamental filtration
technology and Medica’s proprietary technology and expertise, along
with their world-class manufacturing capabilities has enabled
delivery of innovative, high-margin products to customers in
several markets,” said Tod Carpenter, chairman, president and chief
executive officer of Donaldson.
The acquisition is subject, inter alia, to the positive outcome
of the voluntary totalitarian tender offer on the ordinary shares
of Medica, which MavenDanc S.r.l., an Italian company entirely
owned by Donaldson, formally announced to the market on the date
hereof by way of publication of the communication required by
article 102, paragraph 1, of Legislative Decree n. 58 of 24
February 1998 (as amended from time to time) (the "102 Notice").
Copy of the 102 Notice is available to the public on Medica website
at www.medica-spa.com. Upon positive outcome of the tender offer,
Donaldson will acquire a 49% stake of Medica with the option to
acquire the remaining 51% stake in the future. Completion of the
transaction is expected by the third quarter of calendar 2024. Upon
closing, the ratable share of Medica’s earnings would be included
as a part of the Donaldson Life Sciences segment.
Statements in this release regarding future events and
expectations, such as forecasts, plans, trends and projections
relating to Donaldson’s business and financial performance, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and are identified by
words or phrases such as “will likely result,” “are expected to,”
“will continue,” “will allow,” “estimate,” “project,” “believe,”
“expect,” “anticipate,” “forecast,” “plan” and similar expressions.
These forward-looking statements speak only as of the date such
statements are made and are subject to risks and uncertainties that
could affect Donaldson’s performance and could cause Donaldson’s
actual results for future periods to differ materially from any
opinions or statements expressed. These factors include, but are
not limited to, challenges in global operations; impacts of global
economic, industrial and political conditions on product demand;
impacts from unexpected events, including natural disasters;
effects of unavailable raw materials or material cost inflation;
inability to attract and retain qualified personnel; inability to
meet customer demand; inability to maintain competitive advantages;
threats from disruptive technologies; effects of highly competitive
markets with pricing pressure; exposure to customer concentration
in certain cyclical industries; inability to manage productivity
improvements; inability to achieve commitments to ESG; results of
execution of any acquisition, divestiture and other strategic
transactions; vulnerabilities associated with information
technology systems and security; inability to protect and enforce
intellectual property rights; costs associated with governmental
laws and regulations; impacts of foreign currency fluctuations; and
effects of changes in capital and credit markets. These and other
factors are described in Part I, Item 1A, “Risk Factors” of
Donaldson’s Annual Report on Form 10-K for the fiscal year ended
July 31, 2023. Donaldson undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, unless
required by law. The results presented herein are preliminary,
unaudited and subject to revision until Donaldson files its results
with the United States Securities and Exchange Commission on Form
10-Q.
About Donaldson Company,
Inc.
Founded in 1915, Donaldson (NYSE: DCI) is a global leader in
technology-led filtration products and solutions, serving a broad
range of industries and advanced markets. Diverse, skilled
employees at over 140 locations on six continents partner with
customers—from small business owners to R&D organizations and
the world’s biggest OEM brands. Donaldson solves complex filtration
challenges through three primary segments: Mobile Solutions,
Industrial Solutions and Life Sciences. Additional information is
available at www.Donaldson.com.
About Medica S.p.A
Medica Group has been operating since 1985 with its headquarters
in the biomedical district of Mirandola, Italy. Development of
innovative products for blood purification has been the Group’s
core business leveraging R&D strength in hollow fiber membrane
technology, as well as the design and development of electromedical
equipment and related disposables. Today the Group is vertically
integrated, has multiple manufacturing locations, and sales in over
60 countries successfully competing in several markets, namely: 1)
Medical (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC,
pre-transplant organ perfusion, bioregenerative medicine,
gastroenterology, urodynamics, oxygen humidification), 2)
Microbiological purification of water, and 3) Industrial automation
for the biomedical sector. Additional information is available at
www.medica-spa.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240429274041/en/
Sarika Dhadwal (952) 887-3753 Sarika.Dhadwal@Donaldson.com
Donaldson (NYSE:DCI)
過去 株価チャート
から 5 2024 まで 6 2024
Donaldson (NYSE:DCI)
過去 株価チャート
から 6 2023 まで 6 2024